IM Cannabis Corp. filings document a foreign private issuer reporting on Form 6-K, with disclosures centered on its medical cannabis operations in Israel and Germany, material agreements, capital structure and governance. Recent reports cover convertible note and warrant financings, common share conversion terms, registration-statement incorporation by reference, Nasdaq minimum bid price compliance, and executive officer changes.
IMCC regulatory filings also include shareholder-meeting notices, board and management matters, risk-factor and regulatory disclosures, and operating or financial-result updates. The filings describe how financing instruments, common shares, warrants, listing requirements and governance actions affect the company’s public-company reporting framework.
IM Cannabis Corp. files its annual Form 20-F describing a cannabis business focused on medical markets in Israel and Germany while reporting continued losses and liquidity pressure. It recorded operating losses of $11,587 thousand in 2025 and $10,234 thousand in 2024, with an accumulated deficit of $270,210 thousand as of December 31, 2025.
The company discloses negative operating cash flows, high liquidity risk and states that these conditions raise substantial doubt about its ability to continue as a going concern. IM Cannabis depends on equity or debt financing, cost‑saving plans, and regulatory licenses in Israel and Germany, while facing geopolitical, inflationary, regulatory and competitive risks across its operations.
IM Cannabis Corp. reported that it has signed a non-binding letter of intent to acquire 51% of Blackaxe Technologies, a Polish company focused on advanced defense and intelligence solutions. This marks a planned strategic entry into cyber drone interception, satellite intelligence, imagery and AI analytics, and counter‑UAS technologies.
Blackaxe’s systems are based on Israeli technologies aimed at governments, defense organizations and security agencies, reflecting a potential diversification for IMC beyond its existing medical cannabis operations in Israel and Germany. The transaction remains subject to due diligence, definitive agreements, regulatory approvals and customary closing conditions, and there is no assurance it will be completed.
Cannabis Corp. is registering for resale up to 9,788,966 Common Shares on behalf of a single selling shareholder, L.I.A. Pure Capital Ltd. These shares consist of Note Shares from two convertible promissory notes and Warrant Shares from related five-year warrants.
The notes have an aggregate principal of US$2,412,956, bear 8% interest (rising to 14% on default), and are convertible at the lower of a fixed price or 90% of the 20‑day VWAP, subject to floor prices of US$0.29 and US$0.275. The warrants cover 321,821 shares at an exercise price of C$3.45 and are exercisable until January 21, 2031, with 4.99%–9.99% beneficial ownership caps.
The company has already received US$2,132,912 in gross proceeds from the private placements of these notes and warrants, which it plans to use mainly for debt repayment and general corporate purposes. It will not receive proceeds from the registered resale itself, other than any future cash from warrant exercises. As of February 4, 2026, 5,894,812 Common Shares were outstanding; full conversion and exercise scenarios described in the risk factors would substantially increase that share count and could dilute existing holders.
Cannabis Corp. entered into two note purchase agreements with an institutional investor, raising US$2,171,660.40 through convertible notes and accompanying share purchase warrants. The first note has a principal amount of US$1,709,721 and the second note has a principal amount of US$703,725, each bearing interest at 8% per year, increasing to 14% if an event of default occurs.
The notes can be converted into common shares at the lower of a fixed price or 90% of the lowest 20‑day volume‑weighted average price, subject to floor prices of $0.29 and $0.275. The investor also received warrants to purchase up to 228,150 and 93,671 common shares at an exercise price of CAD$3.45 per share, exercisable for five years. A 4.99% beneficial ownership cap limits conversions, and the company plans to use the proceeds for debt repayment and general corporate purposes while committing to file a Form F‑3 resale registration for the underlying shares.
IM Cannabis Corp. appointed Asi Levi as its chief financial officer, effective immediately. He replaces former CFO Uri Birenberg, who resigned from the role for personal reasons.
Levi brings over 15 years of experience in finance and controlling positions, including prior CFO roles at Water Ways Technologies Inc. and DekelOil CI, and controller roles at SciSparc Ltd. and A2Z Cust2Mate Solutions Corp., with expertise in fundraising, financial planning, budgeting, and cash flow management under IFRS and other standards. The company expects to enter into its standard indemnification agreement with Levi on terms consistent with those for its other directors and executive officers, and this leadership change is incorporated by reference into IM Cannabis’s existing registration statements on Form F-3.
IM Cannabis Corp. (IMCC) filed a Form 6-K as a foreign private issuer to notify investors that it has issued a Cancellation Notice for a previously planned special meeting of security holders that was supposed to be held on December 29, 2025. The notice is dated November 14, 2025 and is attached as Exhibit 99.1. This report is also incorporated by reference into the company’s existing Form F-3 registration statements, meaning it becomes part of those registration documents for disclosure purposes.
IM Cannabis Corp. filed a Form 6-K as a foreign private issuer, providing investors with its unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2025. The filing also includes management’s discussion and analysis of financial condition and results of operations for the same periods, along with a press release titled “IM Cannabis Reports Third Quarter 2025 Financial Results.”
Most of this Form 6-K (excluding the “Management Commentary” section of the press release and two certification exhibits) is incorporated by reference into the company’s existing Form F-3 shelf registration statements, meaning this quarterly information now forms part of those registration documents going forward unless later superseded.
IM Cannabis Corp. announced a CFO transition. Chief Financial Officer Uri Birenberg will step down for personal reasons and is expected to continue in the role until January 5, 2026, or an earlier date determined by the company. The company stated his decision was not due to any disagreement regarding operations, policies, or practices.
This 6-K (excluding designated press release paragraphs) is incorporated by reference into IM Cannabis’ Form F-3 registration statements, File Nos. 333-289571 and 333-288346.